Press Release 1GLOBAL taps Nokia voice and packet core solutions to enhance network operations in existing markets, expand new ones Deal swaps out competitors and includes Nokia Evolved Packet Core (EPC), Nokia IMS Voice Core, and Nokia NetGuard security solutions. EPC will be deployed in eight countries, including Australia, the UK, and the US, while Nokia IMS Voice Core will be rolled out in three markets, including the Netherlands.XX January 2025 Espoo, Finland – 1GLOBAL, a leading communications services provider and MVNO active in nine major markets across the globe, has selected Nokia core and security solutions to help the operator enhance and optimize network operations in existing markets like the UK and US, while rolling out services in new territories such as Brazil, South America’s largest telecoms market. Hakan Koç,...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR OTHER MEASURE PURSUANT TO APPLICABLE LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. As previously communicated by Fingerprint Cards AB (publ) (“Fingerprints” or the “Company”), the Company is carrying out a rights issue of units consisting of new shares of series B (“B-shares”) and warrants entitling for subscription of B-shares (“Units”) of up to approximately SEK 159.9 million (the “Rights Issue”). Certain members of the Company’s management and board have, as...

NANO Nuclear Energy Inc.Figure 1 – NANO Nuclear expands intellectual property portfolio to protect proprietary advanced portable ZEUS and ODIN microreactors, as well the KRONOS MMRTM and LOKI MMRTM reactors, all of which are currently in development.New York, N.Y., Jan. 28, 2025 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today highlighted additional important patents recently acquired from Ultra Safe Nuclear Corp. (USNC), which augment protections for NANO Nuclear’s modular microreactor technologies under development. Patent No. US 11,264,141 B2, titled “Composite Moderator for Nuclear Reactor Systems,” relates to the design and construction of composite moderators...

Following Reach Out from Coinbase’s Institutional Team, Worksport Has Created XRP & Bitcoin (BTC) Corporate Accounts West Seneca, New York, Jan. 28, 2025 (GLOBE NEWSWIRE) — Worksport Ltd. (NASDAQ: WKSP) (“Worksport” or the “Company”), a U.S. based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors, is pleased to announce that after evaluating multiple custodians, Worksport has selected Coinbase as its preferred partner, citing Coinbase’s strong regulatory compliance, robust security measures, and insurance-backed custody solutions. This strategic move aligns with Worksport’s Cryptocurrency Treasury Strategy announced on December 5, 2024, wherein the Company expanded its Corporate Treasury and allowed a portion of its surplus cash reserves to be...

MALMÖ, Sweden, Jan. 28, 2025 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY)(“Oatly” or the “Company”) – the world’s original and largest oat drink brand – has teamed up with Nespresso to create a limited-edition coffee made for oat drink lovers. Nespresso’s Oatly Barista Edition Coffee, with its rich and biscuity notes, is the perfect pairing with Oatly’s oat drink and made exclusively for Nespresso Vertuo coffee machines. Creamy, biscuity and indulgent, coffee experts at Nespresso and Oatly co-created the Oatly Barista Edition coffee – blending, roasting and grinding some of the best coffee beans to harmonize with the subtle sweetness of oats. When paired with Oatly, the blend displays strong cereal and sweet aromatics, complemented by a smooth texture, low bitterness, and light body. From Paris, London, New York to Shanghai,...

E-GEN vehicles recently surpassed 10 million cumulative miles, proving the platform’s durability and reliability in real-world conditions. Insights and innovations from the E-GEN platform have directly shaped the development of the W56, raising the bar for durability and performance in the commercial EV market. CINCINNATI, Jan. 28, 2025 (GLOBE NEWSWIRE) — Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today announced that that its E-GEN electric vehicle platform has surpassed 10 million cumulative miles. This milestone underscores Workhorse’s commitment to engineering durable, reliable electric vehicles. Launched nearly a decade ago, the E-GEN platform marked Workhorse’s entry into the commercial...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATESStrategic Expansion with Proposed Acquisition of Alea Health Holdings Limited, a UAE based AI company‏ Proprietary Voice Agent using Conversational AI for onboarding and triaging patients‏ ‏Extended geographic reach – entry into the Middle East Healthcare market‏ ‏Advancing Mental Health Support using Alea’s proprietary and AI powered Mental Health Platform to Augment Primary and Specialist Care‏ ‏Enhanced Bench Strength: Expertise Driving InnovationVANCOUVER, British Columbia, Jan. 28, 2025 (GLOBE NEWSWIRE) — Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“‏‏Treatment‏‏”) is pleased to announce it has entered into a binding letter of intent dated January 28, 2025 (the “‏‏Letter of Intent‏‏”) with...

Celebration, FL, Jan. 28, 2025 (GLOBE NEWSWIRE) — La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company for six agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced that it has fully redeemed and extinguished all of its outstanding warrants (the “Warrants”) previously issued to an institutional accredited investor (the “Holder”). These Warrants, which were exercisable for 2,446,634 shares of common stock of the Company, have now been terminated in their entirety and are no longer exercisable, in accordance with the terms of the Warrant Redemption and Cancellation Agreement (the “Redemption Agreement”) signed by the parties on January 22, 2025. The Company initially issued these Warrants under the securities purchase agreements dated April 1, 2024,...

One of the largest US outpatient medical imaging providers to introduce Xenon MRI platform to its networkPolarean and SimonMed Announce CollaborationPolarean and SimonMed Announce Collaboration to Advance Lung Imaging InnovationDURHAM, NC and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) — Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage leader in advanced medical imaging focused on functional Magnetic Resonance Imaging (“MRI”) of the lungs, announces a strategic collaboration with SimonMed Imaging, one of the largest outpatient medical imaging providers in the United States, to expand access to Polarean’s cutting-edge Xenon MRI platform. SimonMed Imaging operates in over 170 facilities across 11 states, offering comprehensive medical imaging with cutting-edge technology and artificial...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further studies aim to evaluate its impact on metastases Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced promising new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings contribute to validating systemic administration as an effective delivery approach, demonstrating significant tumor growth reduction in orthotopic pancreatic cancer models, a platform designed to mimic human cancer progression. This data underscores SIL-204’s...